Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-04-15

PARVOVIRUS BASED LINEAR ANIMAL VECTORS FOR PRODUCTION OF VACCINES AND OTHER USEFUL PROTEINS

Objetivo

IT IS EXPECTED TO OBTAIN A NEW CLASS OF CLONING VECTORS, WITH INTERESTING PROPERTIES : NOT ONLY THEY ARE NOT ONCOGENIC, BUT THEY MIGHT INHIBIT THE DEVELOPMENT OF SOME TYPES OF TUMORS.
Modification of the genomes of parvoviruses H-1 and MVM, attempting to make them suitable linear vectors, has resulted in:
production of recombinant parvoviruses showing transduction specificity for oncogene-transformed cells and having potential for cancer gene therapy;
programmed cell killing by means of inducible clones of parvoviral genes encoding nonstructural proteins;
demonstration and unravelling of the oncolytic activity of parvoviruses, raising prospects of anticancer applications.

Attempts were made to identify and modify MVM sequences that limit the use of this parvovirus as a vector. An attenuator of virus driven gene expression could be deleted. Since cytotoxic products proved essential for virus replication, a strategy was developed for isolation of cells surviving virus propagation. Oncogenic transformation of a number of human and murine cells enhanced their capacity for expressing MVM and H-1 early genes. The up modulation was especially interesting since these parvoviral nonstructural (NS) proteins were cytotoxic. As a first step towards the construction of an artificial minimchromosome, human deoxyribonucleic acid (DNA) sequences that presumably contain an origin of replication (ori) were isolated, cloned and characterised. However, these sequences no longer functioned as ori after their insertion into circular plasmids, and are now being subcloned in modified parvoviral vectors requiring an exogenous ori for their replication.
THE MOST COMMON GENE VECTOR IS THE CIRCULAR DNA OF BACTERIAL PLASMIDS, WHICH ARE UNABLE TO REPLICATE IN ANIMAL CELLS. GENERALLY, VECTORS FOR ANIMAL CELLS ARE BASED ON ONCOGENIC VIRUSES.

THE PRESENT PROJECT AIMS AT OVERCOMING SUCH LIMITATIONS BY PRODUCING A LINEAR VECTOR CONTAINING PUTATIVE ORIGINS OF MAMMALIAN CELL DNA AND UTILIZING AS FUNCTIONAL TELOMERES THE ENDS OF THE REPLICATIVE FORM OF AUTONOMOUS PARVOVIRUSES.

THESE VIRUSES ARE OF VETERINARY INTEREST, AND VACCINES COULD BE OBTAINED EITHER BY CLONING PARTS OF THEIR GENOME IN E. COLI OR BY MANIPULATING THE VIRUS TO PRODUCE AN APPROPRIATE ANTIGEN IN ANIMAL CELLS. IT IS ALSO PLANNED TO INTRODUCE ANIMAL DNA INTO CONSTRUCTS CONTAINING AT THE TWO ENDS THE TERMINI OF PARVOVIRUS IN ITS REPLICATIVE FORM. ANOTHER INTERESTING PROPERTY OF PARVOVIRUSES IS TO INHIBIT THE DEVELOPMENT OF TUMORS : THE NON PATHOGENIC PARVOVIRAL VECTORS MIGHT BE INTERESTING FOR THIS PURPOSE.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.

Tema(s)

Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.

Datos no disponibles

Convocatoria de propuestas

Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.

Datos no disponibles

Régimen de financiación

Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.

CSC - Cost-sharing contracts

Coordinador

UNIVERSITE LIBRE DE BRUXELLES
Aportación de la UE
Sin datos
Dirección
AV. F.D. ROOSEVELT,50
1050 BRUSSELS
Bélgica

Ver en el mapa

Coste total

Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.

Sin datos

Participantes (2)

Mi folleto 0 0